Total Funding
95
70
Total FundingPost-IPO Equity raised
Growth Score
3 pts
Heat Score
-22 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
56959
Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.
- Mark O'Mahony: Chief Manufacturing Officer
- Gus Lawlor: Chief Operating OfficerPast Role: KPMG, Management Consultant
About the Company
Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development.
